Bridge to Life Enhances Organ Preservation Tech with New Purchase
Bridge to Life Expands with the VitaSmart™ System
Bridge to Life Ltd. has taken a big step in organ preservation through its recent purchase of the VitaSmart™ Hypothermic Oxygenated Machine Perfusion System from Medica S.p.A. This acquisition not only enhances their offerings but also strengthens their position in the transplant medicine space.
Strengthening the Portfolio for Better Transplant Outcomes
The acquisition of the VitaSmart™ system symbolizes a major milestone for Bridge to Life in advancing its mission to improve transplant outcomes. The system has already seen over 5,000 successful liver perfusions performed globally, showcasing its effectiveness and reliability in organ preservation.
CEO Don Webber expressed his excitement about this new addition, stating, "Owning the VitaSmart™ system allows us to support clinicians in implementing Hypothermic Oxygenated Perfusion (HOPE) protocols more effectively." This illustrates the company's commitment to providing user-friendly technology aimed at enhancing organ preservation.
Path to FDA Submission
Bridge to Life is currently in the final stages of preparing its FDA submission for the VitaSmart™ system, with plans to submit in the first quarter of 2025. Webber noted that recent studies indicate impressive clinical outcomes, including a shorter length of hospital stay after transplantation. This bodes well for their potential expansion into U.S. transplant centers and organ procurement organizations, which will benefit patients needing viable liver transplants.
About Medica S.p.A.
Medica S.p.A. operates out of Italy, focusing on biomedical and MedTech products aimed at blood and water purification. Their innovative approach has established them as a significant player in the medical technology sector, providing solutions that complement organizations like Bridge to Life.
About Bridge to Life Ltd
As a leading firm in organ preservation solutions, Bridge to Life is known for its high-quality and innovative products such as Belzer UW® and EasiSlush®. They are dedicated to improving accessibility and quality in the medical field, partnering with top transplant centers and organ procurement organizations worldwide.
Frequently Asked Questions
What is the VitaSmart™ System?
The VitaSmart™ system is a hypothermic oxygenated machine perfusion device used to enhance organ preservation during transplants.
Why did Bridge to Life acquire the VitaSmart™ System?
This acquisition aims to enhance their capabilities in organ preservation and improve transplantation outcomes for patients.
Who is Don Webber?
Don Webber is the CEO and President of Bridge to Life Ltd., a key figure in driving the company's mission and innovations in organ preservation technology.
What are the expected benefits of this acquisition?
The acquisition is expected to expand access to innovative technologies for U.S. transplant centers and ultimately improve patient outcomes.
What is Bridge to Life’s mission?
Bridge to Life’s mission is to improve transplantation outcomes through innovative solutions that save lives and enhance the effectiveness of organ preservation.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.